NEO Rallies 6.5% as RaDaR ST Targets $20B MRD Market

On MAR 19 2026, NEO remained flat at $2.72 in 24-hour trading but saw a 6.54% increase over the past week. Over the last month, the stock declined by 0.29%, and over the past year, it fell by 22.53%. These figures reflect the broader market dynamics and investor sentiment around the company’s recent developments.

NeoGenomics Unveils RaDaR ST to Capture MRD Market Growth

On February 25, NeoGenomics Inc. (NASDAQ:NEO) launched RaDaR ST, a tumor-informed circulating tumor DNA (ctDNA) assay designed to detect molecular residual disease (MRD) across various solid tumor types. This product targets a rapidly expanding MRD market estimated at over $20 billion, which NeoGenomics believes is currently underpenetrated—less than 10% of its potential capacity.

The RaDaR ST assay employs whole-exome sequencing and advanced bioinformatics to track up to 48 tumor-specific variants. It is capable of detecting tumor DNA at 11 parts per million with a 95% probability, ensuring the identification of minimal residual disease. . This high sensitivity enables earlier detection of recurrence compared to traditional imaging, allowing clinicians to intervene more effectively.

The test has been validated through clinical and real-world data in multiple cancer types, including breast and head and neck cancers. It has also received Medicare approval for its initial launch indications, marking a key regulatory milestone.

Expanding Precision Medicine Portfolio

With the introduction of RaDaR ST, NeoGenomics expands its oncology portfolio to cover the full spectrum of cancer care, from initial diagnostic profiling to long-term surveillance. The CEO highlighted that the company’s strategy centers on precision medicine and addressing unmet clinical needs through innovative technologies.

NeoGenomics operates a network of cancer-focused testing laboratories across the U.S. and the U.K., providing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. The RaDaR ST launch aligns with the company’s broader mission to deliver personalized, actionable insights for cancer patients.

Strategic Positioning and Market Potential

The MRD market, though still in its early stages, is growing rapidly due to increasing awareness of the benefits of molecular diagnostics in cancer care. NeoGenomics is well-positioned to capture a significant share of this market with RaDaR ST’s advanced capabilities and regulatory support.

The stock’s 6.54% weekly increase reflects investor optimism around the product’s market potential and NeoGenomics’ ability to innovate in a high-growth sector. While the company continues to face competition and broader market challenges, the launch of RaDaR ST represents a strategic step forward in its mission to improve cancer outcomes through precision medicine.